Figure 2From: A systematic review of gemcitabine and taxanes combination therapy randomized trials for metastatic breast cancerResponse of GT-based combination therapy versus non GT-based combination for metastatic breast cancer. ORR were analyzed with the fixed effect model. (A: Meta-analysis of ORR, subgroup: gemcitabine role; B: Meta-analysis of ORR, subgroup: therapy lines).Back to article page